Haemopep Pharma Gmbh

Other

Pharma Bissendorf Peptide Gmbh

Franz Herbst

Wolf-Georg Forssmann

Gerhard Becker

Jeanette M Alt

Knut Adermann

Peter Schulz-Knappe

Michael Gagelmann

The invention relates to a peptide from human blood, designated as hPTH-(1-37), the structure of which was elucidated for the purpose of the diagnostic, medical and commercial utilization thereof. The isolation of a fragment hPTH-(38-84) proves the existence of the hPTH-(1-37). A removal of amino-terminal amino acids from the hPTH fragment-(1-37) reduces its biological activity. The hPTH-(1-37) circulating in the blood is identical with the synthetic reference substance hPTH-(1-37), however not with fragments such as hPTH-(1-33), hPTH-(1-34) or hPTH-(1-38). The molecule form hPTH-(1-37) has been proven by mass spectrometry (plasma desorption method). A different biological activity and differences in the three-dimensional peptide structure of the hPTH fragment-(1-37) in comparison to other hPTH fragments furnish evidence of that this fragment is the preferential natural peptide of the parathormone family which should be used for the treatment of diseases of the parathyroid, circulatory system, respiratory system, male genital organ and kidneys.

HPTH-fragment-(1-37), the preparation thereof, medicaments containing

Described is a peptide fragment which comprises the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP) and is formed in the kidney. The fragment urodilatin (ANF/CDD 95-126) has the following amino acid sequence: ##STR1## wherein R.sup.1 and R.sup.2 each represent further peptide fragments of ANF/CDD 1-126 (gamma-hANaP). In the amino acid sequence R.sup.1 is Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser and R.sup.2 is Asn-Ser-Phe-Arg-Tyr. Further described are processes for the preparation and/or recovery of the new peptide fragment and a medicament containing urodilatin (ANF/CDD 95-126) as well as medical indications of the medicament.

Cardiodilatin fragment, process for preparing same and use thereof

Described is a peptide fragment which comprises the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP) and is formed in the kidney. The fragment urodilatin (ANF/CDD 95-126) has the following amino acid sequence: ##STR1## wherein R.sup.1 and R.sup.2 each represent further peptide fragments of ANF/CDD 1-126 (gamma-hANaP). In the amino acid sequence R.sup.1 is Thr-Alo-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser and R.sup.2 is Asn-Ser-Phe-Arg-Tyr. Further described are processes for the preparation and/or recovery of the new peptide fragment and a medicament containing urodilatin (ANF/CDD 95-126 ) as well as medical indications of the medicament.

Growing community of inventors

Leimen, Germany

Franz Herbst